Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Rheumatoid arthritis (RA) affects around 1.2% of the adult population. RA is one of the main reasons for work disability and premature retirement, thus substantially increasing social and economic burden. Biological disease-modifying antirheumatic drugs (bDMARDs) were shown to be an effective therap...

Full description

Bibliographic Details
Main Authors: Krzysztof Bonek, Leszek Roszkowski, Magdalena Massalska, Wlodzimierz Maslinski, Marzena Ciechomska
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cells
Subjects:
bDMARDs
biologics
biosimilars
rheumatoid arthritis
genetics
epigenetics
Online Access:https://www.mdpi.com/2073-4409/10/2/323

Internet

https://www.mdpi.com/2073-4409/10/2/323

Similar Items